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Abstract
The Foundation Fighting Blindness is a 50-year old 501c(3) non-profit organization
dedicated to supporting the development of treatments and cures for people
affected by the inherited retinal diseases (IRD), a group of clinical diagnoses that
include orphan diseases such as retinitis pigmentosa, Usher syndrome, and Stargardt
disease, among others. Over $760 M has been raised and invested in preclinical and
clinical research and resources. Key resources include a multi-national clinical consor-
tium, an international patient registry with over 15,700 members that is expanding
rapidly, and an open access genetic testing program that provides no cost compre-
hensive genetic testing to people clinically diagnosed with an IRD living in the United
States. These programs are described with particular focus on the challenges and
outcomes of establishing the registry and genetic testing program.
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1 | INHERITED RETINAL DISEASES
The inherited retinal diseases (IRD) are a group of rare genetic
diseases that affect the neural retina of the eye limited to members of
the Registry who lived in the United States and often lead to a
progressive loss of vision that may result in blindness. Within the
United States it is estimated there are 200,000–300,000 people
affected by an IRD, which projects a worldwide prevalence estimate
of 4.5–6.8 million people (Daiger, Bowne, & Sullivan, 2007; Daiger,
Sullivan, & Bowne, 2013). A recent analysis of just the autosomal
recessive (AR) IRD reported a genetic prevalence of 1 case in 1,380
individuals, with 5.5 million people predicted worldwide (Hanany,
Rivolta, & Sharon, 2020) with 2.7 billion people worldwide (36% of
the population) healthy carriers of at least one mutation that can
cause AR-IRD, possibly among the highest across any group of human
Mendelian diseases. Each of the IRD are orphan diseases. The major-
ity of the diseases are monogenic and over 270 genes have so far
been implicated (RetNet, https://sph.uth.edu/RetNet/) (Daiger,
Rossiter, Greenberg, Christoffels, & Hide, 1998), accounting for
55–60% of the disease burden (Bujakowska et al., 2016; Haer-
Wigman et al., 2017; Zampaglione et al., 2020). Clinically the diseases
can be diagnosed in three broad categories, those that affect the cen-
tral retina initially and increase peripherally over time; those that
affect the periphery first, then spread centrally, and those that are
congenital and stationary. Within each of those categories there is
great diversity in age of onset, rate of progression, and mode of inher-
itance (Sahel, Marazova, & Audo, 2015). Traditional clinical diagnosis
has been based on named disease nomenclature representing the
initial clinical presentation, such as Leber congenital amaurosis, for
early childhood onset disease, retinitis pigmentosa (RP) for diseases
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starting peripherally and moving centrally and Usher syndrome, for
diseases that involved hearing loss in addition to vision loss. With the
increased knowledge about the genetic cause of disease, however,
there has been a greater focus on a gene-specific disease nomencla-
ture. For instance, pathogenic variants in the gene USH2A, while
initially identified as the cause of Usher syndrome type 2A, are now
known to be the most common cause of disease in AR non-syndromic
RP (Pontikos et al., 2020). Similarly, the genes CRX and PRPH2 are
each implicated in at least three different retinal diseases—Leber con-
genital amaurosis, RP, and cone/cone-rod dystrophies (Leroy, Pen-
nesi, & Ohnsman, 2018). For most of the diseases, there is no clear
genotype–phenotype relationship (Cremers, Boon, Bujakowska, &
Zeitz, 2018).
Prior to the 2018 approval of the gene augmentation therapy
Luxturna® (voretigene neparvovec) by the FDA for retinal disease
caused by biallelic pathogenic variants in the RPE65 gene there were
no approved therapies for any IRD. While still the only FDA approved
therapy, there is now a vigorous pipeline of clinical trials with promis-
ing therapies, due in large part to a 50-year history of investment and
advocacy by people affected by IRD in the Foundation Fighting
Blindness.
2 | THE FOUNDATION FIGHTING
BLINDNESS
Earnest research into ocular diseases started in 1968 with the estab-
lishment of the National Eye Institute (NEI). In 1971, to increase
awareness and research into the rare IRD RP, a group of affected
families, led by the Berman and Gund families, formed the National
Retinitis Pigmentosa Foundation. In 1974, the Foundation established
one of the first dedicated research laboratories in the United States,
the Berman-Gund Laboratory led by Dr Eliot Berson at Massachusetts
Eye and Ear at Harvard Medical School, which in 1990 described the
first genetic basis of RP (Dryja et al., 1990) and initiated the near
exponential increase in IRD gene discovery. As the increasing genetic
diversity and overlap between RP and other IRD grew, the Foundation
was renamed to the Foundation Fighting Blindness. The Foundation
continues to invest 25% of its funds in gene discovery and charac-
terization, supporting increasingly sophisticated genetic tools to
discover the genetic cause of the remaining 40–45% of unsolved IRD
cases (Bronstein et al., 2020), and supports a nationwide Israeli IRD
consortium performing clinical and genetic mapping of the entire
Israeli IRD population (Sharon et al., 2020). In total the Foundation
has raised over $760 M for IRD research with an annual research
budget of over $20 M that supports over 73 investigators across
14 countries.
The current mission of the Foundation is to support the develop-
ment of treatments and cures for the inherited retinal dystrophies and
age-related macular degeneration where there are clear genetic
drivers of disease. To achieve this goal, the programs of the Founda-
tion cover a broad spectrum (Shaberman & Durham, 2019) and
include: clinical career development awards for young and established
investigators; individual and multiple investigator preclinical and clini-
cal research awards; mentored translational research acceleration
awards pairing experienced industry drug developers with promising
academic research (https://www.fightingblindness.org/grants-and-
award-programs); non-rodent animal model awards to support the
development of new genetic models with larger eyes; and a
canine IRD facility (Beltran, 2009) co-funded with the NEI to acceler-
ate bench to bedside research in a large clinically relevant eye
(https://www.vet.upenn.edu/research/centers-laboratories/research-
laboratory/experimental-retinal-therapies/publications#2001). Funding
decisions and strategic directions for preclinical and clinical research
are guided by a scientific advisory board of 54 international leading
researchers and clinicians in IRD (https://www.fightingblindness.org/
about/scientific-advisory-board).
3 | CLINICAL CONSORTIUM
Accurate diagnosis, characterization and treatment of patients with
IRD requires both clinical and genetic characterization of disease. In
2013 the Foundation funded an international nine center natural
history study of Stargardt disease due to pathogenic variants in the
ABCA4 gene, ProgStar (NCT01977846) (Strauss et al., 2019) that
resulted in over 14 publications and the identification of relevant
clinical endpoints (http://progstar.org). Building on this model, in
2016 the Foundation created a clinical consortium which currently
consists of over 38 IRD centers of excellence across 11 different
countries (https://public.jaeb.org/ffb/clin). The goal of the consortium
is to accelerate clinical translation of promising therapies by undertak-
ing robust, high-quality, multi-center clinical studies that are shared
openly. Studies generate data using standardized protocols, a central
coordinating center (JAEB) and study-certified reading centers. De-
identified data from the completed trials are archived in an open central
repository to stimulate further hypothesis generation and innovation.
Currently a natural history study of diseases caused by pathogenic
variants in the USH2A gene, called RUSH2A (NCT03146078) is following
127 patients over 4 years is in progress (Duncan et al., 2020) and a sec-
ond study on people with pathogenic variants in the EYS gene called
Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)
(NCT04127006), a cause of AR RP, is also in progress.
4 | THE RD FUND
Historically the Foundation has raised funds through traditional
community-based nonprofit approaches which it invested in awards
to investigators that range from $30,000 to $500,000 per year. How-
ever, to accelerate the pace of clinical progress in moving from labora-
tory drug development to approved clinical products, costs are tens, if
not hundreds, of millions of dollars for each program, and have a very
high failure rate. To meet this challenge requires innovation in funding
models, such as leveraging investments to attract outside venture
capital. To accomplish this, the Foundation launched the Retinal
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Degeneration Fund (RD Fund) in 2018 (https://www.
retinaldegenerationfund.org/) as a 501(c)(3) not-for-profit venture
philanthropy organization. With over $70 million of capital to invest,
the Fund focuses on making mission-related investments, preferably
for programs within 18 months of initiating clinical proof of concept
studies, with any returns reinvested in the Foundation. Currently the
portfolio contains eight companies with investments ranging from
$250 K up to $7.5 M.
5 | MY RETINA TRACKER REGISTRY
One challenge for rare genetic diseases is identifying the affected
population. Few eyecare professionals see a case of an IRD or can
provide a clear diagnosis. A study by Achroma Corp commissioned by
the company AGTC in 2018 showed that for adults with
achromatopsia, the patient journey took over 5 years and on average
seven different healthcare providers for a diagnosis. Notably only
58% of adults and 65% of children with achromatopsia received
genetic testing to support the clinical diagnosis (Achroma Corp, 2018).
Many people affected with an IRD do not complete the diagnostic
journey but instead seek practical support at low vision centers. This
creates barriers to accelerating treatments and cures. It also impacts
our understanding of the true prevalence, clinical diversity, geographic
distribution, age and rate of progression of disease in the population,
and the ease of enrolling eligible patients into research and clinical
studies. Upon commercialization of a therapy this lack of information
about these conditions slows the speed of market penetration, which
are key considerations for investors financing drug development. A
registry easily accessible to people affected by the IRD can help
address these issues.
The Foundation had maintained a patient registry for many years,
that grew to 11,000 names, but was little more than a contact list of
patients with IRD, but had limited disease information. In 2014, to
improve data quality and depth a more detailed on-line registry was
launched, under an Institutional Review Board (IRB) approved
protocol, branded My Retina Tracker® Registry https://www.
fightingblindness.org/my-retina-tracker-registry (Fisher, Bromley, &
Mansfield, 2016). The goals of the Registry are to provide a single,
integrated source of information about, and connection to, all people
with an IRD; and to share those data, de-identified, with researchers
and partners, in order to accelerate the development of treatments
and cures. The Registry provides a convenient, secure database to
aggregate information about people affected with an IRD (Figure 1).
Membership is initiated when an affected person chooses to join and
provides online informed consent to share de-identified data, and be
contacted by Registry staff if there is an opportunity, they may be
interested in. Members own and control their own data. Once
consented, members complete a series of short surveys to capture
their subjective experience of living with their retinal disease, informa-
tion about their health history, how they adjust their life around their
disease, family history, and genetic cause of disease. During a clinical
consult, members can ask their clinician to enter the objective clinical
measurements through a clinical portal (Figure 1). A research portal
enables data analysis of all Registry de-identified data for approved,
external researchers. Members are encouraged to update their
personal surveys at least once a year and the longitudinal data pro-
vides a perspective on disease progression. The member and clinician
surveys use a controlled vocabulary primarily in the form of standard-
ized dropdowns for answers, to facilitate efficient data mining.
In 2020, the Registry underwent a major upgrade. Key upgrades
included enhanced security features; global compliance with data
F IGURE 1 Structure of the My Retina Tracker Registry. People affected with an inherited retinal disease (IRD) join the Registry through a
Member Portal https://www.fightingblindness.org/my-retina-tracker-registry Following an online informed consent, members are presented with
surveys to capture their objective experience of living with an IRD. During a visit to a clinician, the member can request the clinician enter the
clinical ophthalmic exam results through a Clinician Portal on the same web site. To simplify use, clinical data entry is one way, requires no prior
authorization, username or password, and initially enters a holding database. Clinical data is released from the holding database into the members
profile once an algorithm run by the Registry Coordinator identifies a matching profile in the Registry database. Genetic testing data generated by
the CLIA-certified genetic testing partner lab can be downloaded electronically from the lab directly into the registry and matched to the correct
member profile. Both the pdf genetic report and the complete set of sequence variants detected are transferred into the database along with
their classification. Researchers, approved for access, can view and download de-identified data either through a dedicated researcher portal or in
collaboration with the Registry staff who may perform searches on their behalf
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privacy rules, including GDPR and U.S. data and patient protection
laws; and mobile-SMS integration to facilitate new and existing
surveys and provide a more interactive platform. The validated
Patient-Reported Outcomes Measurement Information System®
29 question survey (PROMIS-29), a tool designed to measure self-
reported physical, mental and social health and wellbeing (Cella
et al., 2019) and determine quality adjusted life years (QALYs) (Craig
et al., 2014) was implemented. Other validated patient reported out-
comes (PRO) and outcomes research instruments are planned.
Since launch, over 15,700 people have created an online Registry
profile. The baseline growth of the Registry is 100 new members
per month, but with the introduction of no-cost genetic testing, that
growth has averaged over 370 per month and continues to increase.
The Registry also houses the contact information for the 11,000
registrants from the earlier registry, although many of those have
failed to re-engage, possibly representing the age and history of the
information.
The total 26,700 Registry membership is 48% male, 45% female
with the remainder choosing not to declare their sex and the average
age 50.2 years (±20.6 1SD). For the 15,700 actively engaged members
who have created a profile since the Registry went online, the
membership is 44% male, 43% female with the remainder choosing
not to declare their sex and an average age of 44.3 years (±20.7 1SD).
These differences in the two membership groups align with the
history of the Registry. While most enrollees reside in the United
States (94%), 112 countries are represented, with 18 countries rep-
resenting 75% of the international membership. The most represented
in international membership are: Canada (14%), United Kingdom
(8.9%), India (8.2%), Italy (7.1%), Mexico (6.5%), South Africa (5%),
Australia (4.5%), Poland (4.2%), Germany (3.5%), Argentina (2.2%),
Brazil (1.8%), France (1.7%), Netherlands (1.6%) and New Zealand
(1.3%). Of the international members, 97% have joined recently with
an online profile, the members from the earlier registry being predom-
inantly from Canada.
The composition of the current Registry data by clinical diagnosis
is shown in Figure 2. RP, including Leber congenital amaurosis,
accounts for 51% of the members' diagnoses. Stargardt disease and all
forms of Usher syndrome account for 10% each followed by juvenile
inherited macular dystrophy at 6%. Currently 5% of cases are clinically
characterized as unknown.
Data in the Registry is currently accessible via the Registry staff.
Non-profit use is supported at no cost, while for-profit users sign a
consulting contract to help offset the costs of Registry operation.
De-identified data, lacking names, contact information or demo-
graphics below state/province level can be requested. If researchers
are interested in contacting Registry participants, an IRB approved
contact letter must be submitted to Registry staff outlining the
identity of the interested party, their reason for contacting the Regis-
try member, and contact information for the member to use if they
wish to pursue the opportunity. Once approved, Registry staff send a
F IGURE 2 Composition of the My Retina Tracker Registry. The composition of the current Registry membership, by clinical diagnosis, for the
15,700 members with an online profile
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contact letter to the selected Registry members. The decision to iden-
tify themselves or not rests entirely with the member, and subsequent
interactions with the interested party are independent of the Registry.
External interest in the Registry grew rapidly. There have been
over 44 substantial requests for data including requests to: help enroll
in nine clinical trials, multiple natural history studies and multiple focus
groups; provide prevalence for specific genes, variants and
technology-specific attributes; provide DNA for preclinical research;
promote IRD disease specific conferences; and support a Retina Inter-
national survey on the economic impact of blindness.
6 | REMOVING THE ACCESS BARRIER FOR
GENETIC TESTING
The current preclinical and clinical pipelines for the IRD are heavily
weighted toward gene and variant specific diseases. The first FDA
approved in vivo gene augmentation therapy is specific to the RPE65
gene, and there is a pipeline of 15 different gene augmentation trials
for the IRD in over 24 different clinical trials. Similarly, the first human
in vivo CRISPR/Cas9 gene editing clinical trial, sponsored by Editas Med-
icine and Allergan is for a specific variant in intron 26 (c.2991+1655AG,
p.Cys998X) of the CEP290 gene, as are antisense oligonucleotide-based
variant specific trials by ProQR for the USH2A gene exon 13 mutation
(c.2299delG, p.Glu767Serfs*21), RHO gene (c.68C>A, p.Pro23His), and
CEP290 gene (c.2991+1655AG, p.Cys998X) variants. The genetic cause
has become a critical component augmenting a clinical diagnosis. Prior to
2017 10% of My Retina Tracker Registry members reported having
a genetic test.
In January 2017 the Foundation launched a pilot program to
understand the patient and clinical interest in genetic testing by
funding a comprehensive IRD genetic testing and counseling service
at no cost to patient, clinician or insurance. The program was limited
to people living in the United States and designed to address the
problems faced within the United States for access to testing. Models
seeking to minimize the cost using patient insurance were considered,
but reimbursement rules, and the Foundation acting essentially as a
co-insurer, created administrative complications and would specifi-
cally exclude Medicaid patients who only receive last resort coverage.
To reduce the Foundations administrative workload, and provide
a consistent dataset for later analysis, a single genetic testing provider
was selected. Key considerations were for a comprehensive IRD gene
panel test with strong coverage of the genetic regions known to be
difficult, such as the 1kb long purine rich region of ORF15 within the
RPGR gene (Vervoort et al., 2000; Vervoort & Wright, 2002) which is
reported to account for 80% of all cases of RPGR mutations, sensitiv-
ity for the increasing number of deep intronic pathogenic variants
being discovered in genes like ABCA4 (Sangermano et al., 2019), and
high sensitivity copy number detection, since these variants may rep-
resent 9% of IRD cases (Zampaglione et al., 2020).
Turn-around time was also important. In the past, Registry mem-
bers had sought Registry staff help to obtain results for genetic testing
they had participated in many years prior. Expecting results in weeks,
members expressed frustration and lack of confidence in testing when
there had been no communication of results after a year, often more,
and their enquiries not returned. In most cases the member had
participated in an academic research study, which had failed to
identify a genetic cause. Communicating the difference between
research studies and a CLIA-certified test, and education that a
CLIA-certified test would provide a prompt result, even if negative,
was important. Given the complexity of a genetic result, and the
enquiries we had previously from constituents who had been tested,
but results had not been explained to them, genetic counseling was
considered an essential aspect for our program. Genetic counseling
was provided through genetic counselors associated with IRD centers
when available, or otherwise provided by InformedDNA telegenetic
counselors who could support patients nationwide. Blueprint Genetics
was selected as the genetic testing lab.
The pilot program was an IRB approved protocol within the
Registry Protocol. Eligibility was limited to members of the Registry
who lived in the United States, who completed an informed consent,
had not previously had a relevant comprehensive gene panel test, and
agreed to upload the result into their de-identified Registry profile. To
order the test a clinician was required to enter, at minimum, a clinical
diagnosis of an IRD and a recent best corrected visual acuity (BCVA)
into the Registry clinical portal. Registry staff confirmed all eligibility
criteria before approving Blueprint Genetics to test and invoice the
Foundation. During genetic counseling, the test result was entered
into the Registry clinical portal, before invoicing the Foundation.
Initially 10 clinicians with a strong IRD expertise were approved to
order the test. Demand from patients and clinicians to expand the
program led, over 22 months, to over 180 approved clinicians across
149 geographically diverse practice groups, of which 40% were aca-
demic and 60% private, ordering over 6,300 tests. An analysis by
InformedDNA of referral data from two of the clinics with the highest
referral rates, showed that prior to the program 75% of patients
referred for testing reported they did not complete pre-test genetic
counseling appointments or obtain genetic testing, primarily because
of lack of insurance coverage and/or cost, with genetic counseling, or
testing, or both. The program reversed the trend with >98% participa-
tion of referred patients completing genetic testing through this
research protocol. In 2019 a survey of the satisfaction with genetic
counseling showed that 98% considered the counseling important,
feeling more informed about their genetic risks and better equipped
to make informed decisions about their retinal condition.
As demand from the program grew, the Foundations administra-
tive burden ensuring eligibility and tracking invoicing became
unscalable. Common challenges were patients not being in the Regis-
try, clinicians overlooking the entry of the diagnosis and/or BCVA in
the Registry and the need for ordering clinicians, especially in aca-
demic centers, to seek their IRB approval before submitting patient
data into the third-party Registry. These created significant backlogs
in the testing pipeline, delaying results to patients.
To scale more efficiently an Open Access genetic testing program
was launched in October 2019 using a recently expanded retinal dys-
trophy panel (including mitochondrial genes) of 322 genes offered by
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Blueprint Genetics (https://blueprintgenetics.com/tests/panels/
ophthalmology/retinal-dystrophy-panel/). The key innovations were:
removing the need for a patient to be a member of the Registry;
capturing the required patient online consent and clinical data in a
custom online ordering portal of Blueprint Genetics; offering member-
ship in the Registry during genetic counseling; and electronic export
of the patient, clinical and test result data from Blueprint Genetics
into the Registry for those who are, or become, members of the
Registry. Clinicians no longer needed to enter data into a third-party
Registry, removing the need for their IRB approval. Participants are
informed about the Registry during genetic counseling and, if asked,
the counselors assist the participant with the Registry informed
consent and register them online.
Family variant testing is provided by the program for other
affected family members of the proband in selected cases when infor-
mative in: determining phase for recessive disease that might support
eligibility for a therapy in or near clinical trials; in strengthening variant
classification; or testing other affected family members. Given the lack
of genotype–phenotype correlation and potential psychological
impact of a pathogenic genetic diagnosis, the Foundation has
refrained from providing carrier or pre-symptomatic testing.
As anticipated, the clinician base ordering the Open Access
program grew promisingly prior to COVID-19 closures, but also
highlighted the expense of scaling. While the program has been
funded primarily by generous grants from the non-profit George Gund
Foundation, and other patient advocacy groups, such as Sofia Sees
Hope, a sustainable program depends on creating value for industry
partners. Genetic data has multiple values to industry: to guide
product development, based on market size for a gene or variant
specific technology; and to aid in recruitment of patients for focus
groups, natural history studies and clinical trials. More important,
however, is to support rapid market penetration when a product
reaches market. As mentioned previously, many IRD are relatively rare
and any single IRD center of excellence may only be aware of a hand-
ful of genotyped patients, meeting eligibility criteria, to complete
clinical trials. However, rare disease space market penetration requires
an ability to rapidly find the majority of patients who are dispersed
throughout the broader community. With little genotype–phenotype
correlation, their identification depends on a broader genetic screen-
ing program, an expensive undertaking for a single industry partner,
especially smaller biotech companies who pioneer the IRD therapeutic
space. Using a nominal price of $1,000 for a comprehensive IRD panel
genetic test, a gene accounting for 5% of RP will, on average, require
20 tests ($20,000) to find one person among those with a clinical
diagnosis of RP. This cost is multiplied by the prevalence of a variant
within that genetic subgroup, and several-fold more again if eligibility
criteria such as age, percent viable photoreceptors, patient interest in
a specific therapy, or other are applied. Any bias in the composition of
the patient population being tested further impacts cost. Given many
genes, or specific genetic variants are below a 1% incidence the
identification cost of a single eligible patient can rapidly become hun-
dreds of thousands of dollars. Industry cost-sharing a genetic testing
program through a non-profit Foundation is an attractive alternative.
Industry is currently focused on a handful of the 270 IRD genes, with
multiple industry partners overlapping therapeutic gene targets, but
careful design can ensure all parties benefit, while also benefitting the
entire IRD patient population with a genetic understanding of their
disease and shared with the entire research community through My
Retina Tracker Registry. The Foundation, in collaboration with Blue-
print Genetics and InformedDNA is currently forging a new model to
achieve this partnership model. Several early industry partners
supporting the development of this program are acknowledged on the
Open Access Genetic Testing Program website (https://www.
fightingblindness.org/open-access-genetic-testing-program). One limi-
tation of this program is its restriction to the United States and the
need to address the unique challenges presented by the structures of
the U.S. healthcare and insurance environment. In the future the
Foundation is interested in exploring extension of this program to a
broader international community, which may require different consid-
erations and a different structure to address those environments.
7 | GENETIC TESTING OUTCOMES
Currently over 8,600 of the approximately 15,700 Registry members
have had a genetic test, with over 7,600 of those being provided by





Genes in order of descending
incidence
Top 5 genes 48.2 ABCA4 (19.0%), USH2A (12.9%),
RPGR (6.8%), PRPH2 (4.8%), RHO
(4.7%)
Top 10 genes 59.9 + EYS (2.6%), BEST1 (2.4%),
PRPF31 (2.4%), CRB1 (2.3%), RS1
(2.0%)
Top 20 genes 72.1 + CHM (1.7%), BBS1 (1.7%), RP1
(1.7%), PROM1 (1.1%), PDE6B
(1.1%), CRX (1.1%), MYO7A
(1.0%), NR2E3 (1.0%), CNGA3
(1.0%), RDH12 (0.8%)
Top 25 genes 76.0 + RP2 (0.8%), CNGB3 (0.8%),
ADGVR1 (0.8%), CERKL (0.8%),
CEP290 (0.7%)
Top 54 genes 88.9 + GUCY2D (0.7%), SAG, CNGB1,
IMPG2, FAM161A (0.6%),
MERTK, SNRNP200, CACNA1F
(0.5%), RPE65, MAK, RP1L1,
CNGA1, CDH23, IMPDH1, CLN3,
PDE6A (0.4%), CDHR1, ALMS1,
PRPF8, PCARE, GUCA1A, TULP1,
NYX, IFT140, RPGRIP1, PRPF3,
HK1, KIZ, CLRN1 (0.3%)
Note: The causative genes for the first 5,879 cases submitted to the My
Retina Tracker Genetic Testing Program are provided in rank order for the
cases that received a clear genetic result (pathogenic or likely pathogenic
variants). The incidence of each gene () is provided for the top 25 genes
with key steps in incidence indicated for the bottom 29 genes.
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the Registry genetic testing programs. A breakdown of the genetic
causes of disease for the first 5,879 probands tested is shown in
Figure 2. One hundred and forty-eight genes were implicated in a
clear genetic diagnosis. Of these the top five genes: ABCA4 (20%)
USH2A (13%), RPGR (7%), PRPH2 (5%) and RHO (5%) accounted for
almost 50% of the genetic diagnoses, and the top 25 genes accounted
for just over 75% of the genetic causes (Table 1). These results for the
U.S. population are similar to the findings of a similarly sized U.K. IRD
population study (Pontikos et al., 2020). Notable differences within
the top five genes were a 1.5-fold higher incidence of RHO in the
U.S. population, consistent with the founder effect of the RHO P23H
variant (Farrar et al., 1990), accompanied by a similar 2.2-fold
increased incidence of EYS, the most common cause of AR RP. While
the incidences may be more broadly representative of the genetic
incidence of IRD in the United States than single site studies (Stone
et al., 2017), we anticipate more accuracy as the Open Access genetic
testing program expands to a wider spectrum of referring clinicians.
The overall diagnostic yield, using testing laboratory variant classifica-
tions, was 59.4% across all IRD. This was calculated for autosomal domi-
nant disease and X-linked disease by requiring one pathogenic or likely
pathogenic variant, while for AR disease it was based on two pathogenic
and/or likely pathogenic variants or the combination of a pathogenic or
likely pathogenic with a variant of unknown significance. By clinical diag-
nosis, syndromic diseases such as Usher Syndrome and Bardet Biedl Syn-
drome had the highest detection rates of 83%, while cone and cone/rod
dystrophies had the lowest detection rates 50% (Table 2). A more
detailed analysis of the results is being prepared for publication.
8 | CONCLUSION
Non-profit organizations, like the Foundation Fighting Blindness, can
play critical roles in helping to catalyze and de-risk drug development
in rare disease spaces like the IRD by a variety of strategies that
include incentivizing clinician scientists to commit to these fields,
supporting early preclinical and clinical work, sponsoring natural history
studies that share data widely, and leveraged investments supporting
key proof of concept studies in humans. Clinical characterization of
patients, supported by a comprehensive genetic testing program, and
natural history studies are also critical. Through implementation of a
patient Registry, the patient perspective of disease, and ease of accessi-
bility to rare disease patients can be facilitated. Foundations can partner
with other organizations and industry partners and, by removing cost
barriers, ensure all people diagnosed with an inherited disease can
receive an accurate genetic diagnosis.
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